Comparative Pharmacology
Head-to-head clinical analysis: PREFRIN A versus VISINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREFRIN A versus VISINE.
PREFRIN-A vs VISINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Approximately 1-2 hours for ocular absorption; systemic half-life not clinically relevant due to low systemic absorption
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Primarily renal as unchanged drug and metabolites; minor biliary/fecal elimination (<10%)
Category C
Category C
Ophthalmic Decongestant/Antihistamine Combination
Ophthalmic Decongestant